These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8538200)

  • 41. Dehydroepiandrosterone 7alpha- and 7beta-hydroxylation in mouse brain microsomes. Effects of cytochrome P450 inhibitors and structure-specific inhibition by steroid hormones.
    Doostzadeh J; Cotillon AC; Morfin R
    J Neuroendocrinol; 1997 Dec; 9(12):923-8. PubMed ID: 9468017
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms.
    Simoncini T; Mannella P; Fornari L; Varone G; Caruso A; Genazzani AR
    Endocrinology; 2003 Aug; 144(8):3449-55. PubMed ID: 12865324
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 7-Hydroxy androstene steroids and a novel synthetic analogue with reduced side effects as a potential agent to treat autoimmune diseases.
    Auci DL; Reading CL; Frincke JM
    Autoimmun Rev; 2009 Mar; 8(5):369-72. PubMed ID: 19071234
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral dehydroepiandrosterone inhibits the growth of human pancreatic cancer in nude mice.
    Muscarella P; Boros LG; Fisher WE; Rink C; Melvin WS
    J Surg Res; 1998 Oct; 79(2):154-7. PubMed ID: 9758731
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential effects of dehydroepiandrosterone and deoxyribonucleosides on DNA synthesis and de novo cholesterogenesis in hepatocarcinogenesis in rats.
    Feo F; Daino L; Seddaiu MA; Simile MM; Pascale R; McKeating JA; Davliakos GP; Sudol KS; Melhem MF; Rao KN
    Carcinogenesis; 1991 Sep; 12(9):1581-6. PubMed ID: 1680032
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of glucose-6-phosphate dehydrogenase inhibition in the antiproliferative effects of dehydroepiandrosterone on human breast cancer cells.
    Di Monaco M; Pizzini A; Gatto V; Leonardi L; Gallo M; Brignardello E; Boccuzzi G
    Br J Cancer; 1997; 75(4):589-92. PubMed ID: 9052415
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Studies on the anti-tumorpromotion activities of dehydroepiandrosterone and its mechanism of action].
    Yang S; Fu ZD; Han R
    Yao Xue Xue Bao; 2001 Aug; 36(8):576-80. PubMed ID: 12579932
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antihyperglycemic effect of dehydroepiandrosterone analogue 16 alpha-fluoro-5-androsten-17-one in diabetic mice.
    Pashko LL; Schwartz AG
    Diabetes; 1993 Aug; 42(8):1105-8. PubMed ID: 8325440
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of a 3-week dehydroepiandrosterone administration on sleep, sex steroids and multiple 24-h hormonal profiles in postmenopausal women: a pilot study.
    Caufriez A; Leproult R; L'Hermite-Balériaux M; Kerkhofs M; Copinschi G
    Clin Endocrinol (Oxf); 2013 Nov; 79(5):716-24. PubMed ID: 23488643
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential effects of dehydroepiandrosterone and testosterone in prostate and colon cancer cell apoptosis: the role of nerve growth factor (NGF) receptors.
    Anagnostopoulou V; Pediaditakis I; Alkahtani S; Alarifi SA; Schmidt EM; Lang F; Gravanis A; Charalampopoulos I; Stournaras C
    Endocrinology; 2013 Jul; 154(7):2446-56. PubMed ID: 23696568
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effects of dehydroepiandrosterone on carcinogenesis, obesity, the immune system, and aging.
    Williams JR
    Lipids; 2000 Mar; 35(3):325-31. PubMed ID: 10783010
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is DHEA replacement beneficial in chronic adrenal failure?
    Lang K; Burger-Stritt S; Hahner S
    Best Pract Res Clin Endocrinol Metab; 2015 Jan; 29(1):25-32. PubMed ID: 25617170
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is vulvovaginal atrophy due to a lack of both estrogens and androgens?
    Labrie F; Martel C; Pelletier G
    Menopause; 2017 Apr; 24(4):452-461. PubMed ID: 27875388
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Might DHEA be considered a beneficial replacement therapy in the elderly?
    Genazzani AD; Lanzoni C; Genazzani AR
    Drugs Aging; 2007; 24(3):173-85. PubMed ID: 17362047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5-steroids in the ZR-75-1 human breast cancer cell line.
    Poulin R; Labrie F
    Cancer Res; 1986 Oct; 46(10):4933-7. PubMed ID: 2944574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids.
    Genazzani AD; Stomati M; Bernardi F; Pieri M; Rovati L; Genazzani AR
    Fertil Steril; 2003 Dec; 80(6):1495-501. PubMed ID: 14667889
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury.
    Gordon GB; Bush DE; Weisman HF
    J Clin Invest; 1988 Aug; 82(2):712-20. PubMed ID: 2969922
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
    Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
    J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Exceptional chemopreventive activity of low-dose dehydroepiandrosterone in the rat mammary gland.
    McCormick DL; Rao KV; Johnson WD; Bowman-Gram TA; Steele VE; Lubet RA; Kellof GJ
    Cancer Res; 1996 Apr; 56(8):1724-6. PubMed ID: 8620482
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dehydroepiandrosterone substitution in female adrenal failure: no impact on endothelial function and cardiovascular parameters despite normalization of androgen status.
    Christiansen JJ; Andersen NH; Sørensen KE; Pedersen EM; Bennett P; Andersen M; Christiansen JS; Jørgensen JO; Gravholt CH
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):426-33. PubMed ID: 17302879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.